{"id":"docetaxel-capecitabine-followed-by-xec","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hand-foot syndrome"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel stabilizes microtubules and prevents their disassembly, halting mitosis in cancer cells. Capecitabine is converted to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis. The XEC regimen delivers additional chemotherapy agents with complementary mechanisms: cyclophosphamide alkylates DNA, epirubicin intercalates DNA and generates reactive oxygen species, and 5-fluorouracil again targets nucleotide synthesis.","oneSentence":"This regimen combines docetaxel (a microtubule-stabilizing chemotherapy) and capecitabine (a fluoropyrimidine prodrug) followed by XEC (a combination of cyclophosphamide, epirubicin, and 5-fluorouracil) to inhibit cancer cell division and induce apoptosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:42.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (neoadjuvant or adjuvant setting)"}]},"trialDetails":[{"nctId":"NCT01642771","phase":"PHASE3","title":"Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"China Breast Cancer Clinical Study Group","startDate":"2012-06","conditions":"Breast Cancer","enrollment":636}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Capecitabine: Xeloda"],"phase":"phase_3","status":"active","brandName":"Docetaxel/capecitabine followed by XEC","genericName":"Docetaxel/capecitabine followed by XEC","companyName":"China Breast Cancer Clinical Study Group","companyId":"china-breast-cancer-clinical-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This regimen combines docetaxel (a microtubule-stabilizing chemotherapy) and capecitabine (a fluoropyrimidine prodrug) followed by XEC (a combination of cyclophosphamide, epirubicin, and 5-fluorouracil) to inhibit cancer cell division and induce apoptosis. Used for Breast cancer (neoadjuvant or adjuvant setting).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}